Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2013 Sep 7;20(1):4–13. doi: 10.1016/j.bbmt.2013.08.012

Figure 1. Donor-Cell Consolidation of Remission for AML Relapse after AlloSCT.

Figure 1

Analysis of EBTR data from 38 patients in CR after first-line cytoreductive therapy for relapsed AML after AlloSCT demonstrated improved OS with use of donor cells for consolidation: 55 ± 11% vs. 20 ± 10% (p=.038); DLI and second AlloSCT were considered as time-dependent variables. Adapted from: Schmid C., et al. (Blood 2012;119:1599-1606).